In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Natco Fights Back After Charges Of Marketing Substandard Albupax Drug; Says Test Kits Yielding Varying Results

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Controversy over the charges leveled by India's drug controller on Natco Pharma for allegedly selling substandard anti-cancer drug Albupax thickened as the Hyderabad-headquartered company openly blamed competition for "resorting to an insidious campaign through selective leaks and half-truths to malign its image and reputation.

You may also be interested in...

India's Natco Eyes Generic For Celgene's Mega Brand Revlimid; Will REMS Scuttle The Move?

MUMBAI - Although U.S.-headquartered Celgene succeeded last year in preventing India's Dr. Reddy's Labs from conducting bioequivalence studies on its fast-growing multiple myeloma drug Revlimid (lenalidomide) - due to risk management and restricted distribution issues - it may have a much harder fight on its hands now

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts